Thrombocytopenia in cancer patients

Thrombosis Research

Volumn 133, Issue SUPPL. 2, 2014, Pages

  Liebman, Howard A ^a  

^a UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

Author keywords

Cancer; Chemotherapy; Platelet transfusions; Thrombocytopenia

Indexed keywords

ALEMTUZUMAB; AMINOCAPROIC ACID; AZATHIOPRINE; CARBOPLATIN; CISPLATIN; CORTICOSTEROID; CYCLOPHOSPHAMIDE; CYTOTOXIC AGENT; DEXAMETHASONE; ELTROMBOPAG; ETOPOSIDE; FLUOROURACIL; FOLINIC ACID; GEMCITABINE; IFOSFAMIDE; IMMUNOGLOBULIN; IRINOTECAN; MITOMYCIN; NITROSOUREA; OXALIPLATIN; PACLITAXEL; PREDNISONE; RITUXIMAB; ROMIPLOSTIM; SUNITINIB; TRANEXAMIC ACID; ANTINEOPLASTIC AGENT; MYELOABLATIVE AGENT;

ABLATION THERAPY; ACUTE LEUKEMIA; ALLOGENEIC STEM CELL TRANSPLANTATION; APLASIA; ARTICLE; AUTOIMMUNE HEMOLYTIC ANEMIA; AUTOLOGOUS STEM CELL TRANSPLANTATION; BLEEDING; BONE MARROW; BREAST CANCER; CANCER CHEMOTHERAPY; CANCER PATIENT; CHRONIC LYMPHATIC LEUKEMIA; COLON CANCER; CORTICOSTEROID THERAPY; DIFFERENTIAL DIAGNOSIS; DISSEMINATED INTRAVASCULAR CLOTTING; DRUG MEGADOSE; GASTROINTESTINAL STROMAL TUMOR; HEMATOLOGIC MALIGNANCY; HEMOLYTIC UREMIC SYNDROME; HODGKIN DISEASE; HUMAN; IDIOPATHIC THROMBOCYTOPENIC PURPURA; KIDNEY CARCINOMA; LUNG ADENOCARCINOMA; LUNG CANCER; LYMPHOCYTE PROLIFERATION; LYMPHOMA; MULTIPLE SCLEROSIS; OVARY CANCER; PANCREATIC NEUROENDOCRINE TUMOR; PRIORITY JOURNAL; PROSTATE CANCER; SPLEEN; SPLENECTOMY; STEM CELL TRANSPLANTATION; T LYMPHOCYTE; THROMBOCYTE; THROMBOCYTE COUNT; THROMBOCYTE TRANSFUSION; THROMBOCYTOPENIA; THROMBOTIC THROMBOCYTOPENIC PURPURA; TRANSFUSION; BLOOD; CHEMICALLY INDUCED; COMPLICATION; IMMUNOLOGY; NEOPLASMS;

ANTINEOPLASTIC AGENTS; HUMANS; MYELOABLATIVE AGONISTS; NEOPLASMS; STEM CELL TRANSPLANTATION; THROMBOCYTOPENIA;

EID: 84901435334     PISSN: 00493848     EISSN: 18792472     Source Type: Journal    
DOI: 10.1016/S0049-3848(14)50011-4     Document Type: Article

References (116)

1. A.I. Kuznetsov, A.L. Ivanov, L.I. Idelson, and A.V. Mazurov Mechanisms of thrombocytopenia in patients with lymphoproliferative diseases Eur J Haematol 49 1992 113 118
2. L.S. Elting, E.B. Rubenstein, C.G. Martin, D. Kurtin, S. Rodriguez, and E. Laiho et al. Incidence, Cost, and Outcomes of Bleeding and Chemotherapy Dose Modification Among Solid Tumor Patients With Chemotherapy-Induced Thrombocytopenia J Clin Oncol 19 2001 1137 1146 (Pubitemid 32176291)
3. T. Andre, C. Boni, L. Mounedji-Boudiaf, M. Navarro, J. Tabernero, and T. Hickish et al. Oxaliplatin, fluorouracil and leucovorin as adjuvant treatment for colon cancer N Engl J Med 350 2004 2324 2351
4. E. Van Cutsem, C.-H. Kohne, E. Hitre, J. Zaluski, C.-R. Chang Chien, and A. Makhson et al. Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer N Engl J Med 360 2009 1408 1417
5. T.S. Mok, Y.-L. Wu, S. Thongprasert, C.-H. Yang, D.-T. Chu, and N. Saijo et al. Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma N Engl J Med 361 2009 947 957
6. R.F. Ozols Update on the management of ovarian cancer Cancer J 2 suppl1 2002 S22 S30
7. M. Markmann, B. Reichman, T. Hakes, W. Jones, J.L. Lewis Jr, and S. Rubin et al. Responses to second-line cisplatin-based intraperitoneal therapy in ovarian cancer: influence of a prior response to intravenous cisplatin J Clin Oncol 9 1991 1801 1805
8. P.A. Vasey "Dose dense" chemotherapy in ovarian cancer Int J Gynecol Cancer 15 Suppl 3 2005 226 232 (Pubitemid 43096588)
9. H. Ishikawa, K. Fujiwara, S. Suzuki, Y. Tanaka, and I. Kohno Platelet-sparing effect of paclitaxel in heavily pretreated ovarian cancer patients Int J Clin Oncol 7 2002 330 333 (Pubitemid 35332296)
10. R. Sharma, J. Graham, S. Blagden, and H. Gabra Sustained platelet-sparing effect of weekly low dose paclitaxel allows effective, tolerable delivery of extended dose dense weekly carboplatin in platinum resistant/refractory epithelial ovarian cancer BMC Cancer 11 2011 289 298
11. E. Pertusini, J. Ratajczak, M. Majka, D. Vaughn, M.Z. Ratajczak, and A.M. Gewirtz Investigating the platelet-sparing mechanism of paclitaxel/carboplatin combination chemotherapy Blood 97 2001 638 644 (Pubitemid 32113395)
12. G.K. Dy, and A.A. Adjei Understanding, recognizing and managing toxicities of targeted anticancer therapies CA Cancer J Clin 63 2013 249 279
13. R.J. Motzer, T.E. Hutson, P. Tomczak, N.D. Michaelson, R.M. Bukowski, and M.W. Shah et al. Overall survival updated results for sunitinib compared with interferon alfa in patients with metastatic renal cell carcinoma J Clin Oncol 27 2009 3584 3590
14. E. Raymond, L. Dahan, J.L. Raoul, Y.J. Bang, L. Borbath, and C. Lombard-Bohas et al. Sunitinib malate for treatment of pancreatic neuroendocrine tumors N Engl J Med 364 2011 601 613
15. G.D. Demetri, A.T. Van Osterom, C.R. Garret, M.E. Blackstein, M.H. Shah, and J. Verweij et al. Efficacy and safety of Sunitinib in patients with advanced gastrointestinal stromal tumor after failure of imatinib: A randomized control trial Lancet 368 2006 1329 1338 (Pubitemid 44528723)
16. D.B. Mendel, A.D. Laird, X. Xin, S.G. Louie, J.G. Christensen, and G. Li et al. In vivo antitumor activity of SU11248, a novel tyrosine kinase inhibitor targeting vascular endothelial growth factor and platelet derived-growth factor receptors: determination of the pharmacokinetic/pharmacodynamic relationship Clin Cancer Res 9 2003 327 337 (Pubitemid 36109749)
17. T. Funakoshi, A. Latif, and M.D. Galsky Risk of hematologic toxicities in cancer patients treated with sunitinib: A systematic review and meta-analysis Cancer Treat Rev 39 2013 818 830
18. M.J. Bishton, S.J. Harrison, B.P. Martin, N. McLaughlin, C. James, and E.C. Joselsson et al. Deciphering the molecular and biologic processes that mediate histone deacetylase inhibitor-induced thrombocytopenia Blood 117 2011 3658 3668
19. H. Matsuoka, A. Unami, T. Fujimura, T. Noto, Y. Takata, and K. Yoshizawa et al. Mechanisms of HDAC inhibitor-induced thrombocytopenia Eur J Pharmacol 571 2007 88 96 (Pubitemid 47379689)
20. I. Tepler, L. Elias, J.W. Smith 2nd, M. Hussein, G. Rosen, and A.Y. Chang et al. A randomized placebo-controlled trial of recombinant human interleukin-11 in cancer patients with severe thrombocytopenia due to chemotherapy Blood 87 1996 3607 3614 (Pubitemid 26129588)
21. M.S. Cairo, V. Davenport, O. Bessmertny, S.C. Goldman, S.L. Berg, and S.G. Kreissman et al. Phase I/II dose escalation study of recombinant human interleukin-11 following ifosfamide, carboplatin and etoposide in children and young adults with solid tumours or lymphoma: A clinical, haematological and biological study Br J Haematol 128 2004 49 58
22. T.D. Bartley, J. Bogenberger, P. Hunt, Y.S. Li, H.S. Lu, and F. Martin et al. Identification and cloning of a megakaryocyte growth and development factor that is a ligand for the cytokine receptor Mpl Cell 77 1994 1117 1124
23. S. Lok, K. Kaushansky, R.D. Holly, J.L. Kuijper, C.E. Lofton-Day, and P.J. Oort et al. Cloning and expression of murine thrombopoietin cDNA and stimulation of platelet production in vivo Nature 369 1994 565 568 (Pubitemid 24192525)
24. F.J. de Sauvage, P.E. Hass, S.D. Spencer, B.E. Malloy, A.L. Gurney, and S.A. Spencer et al. Stimulation of megakaryocytopoiesis and thrombopoiesis by the c-Mpl ligand Nature 369 1994 533 538
25. M. Fanucchi, J. Glaspy, J. Crawford, J. Garst, R. Figlin, and W. Sheridan et al. Effects of polyethylene glycol-conjugated recombinant human megakaryocyte growth and development factor on platelet counts after chemotherapy for lung cancer N Engl J Med 336 1997 404 409 (Pubitemid 27081903)
26. R.L. Basser, J.E. Rasko, K. Clarke, J. Cebon, M.D. Green, and A.P. Grigg et al. Randomized, blinded, placebo-controlled phase I trial of pegylated recombinant human megakaryocyte growth and development factor with filgrastim after dose-intensive chemotherapy in patients with advanced cancer Blood 89 1997 3118 3128
27. J. Crawford, J. Glaspy, and C. Belani et al. A randomized, placebo-controlled, blinded, dose scheduling trial of pegylated recombinant human megakaryocyte growth and development factor (PEG-HUMGDF) with filgrastim support in non-small cell lung cancer (NSCLC) patients treated with paclitaxel and carboplatin during multiple cycles of chemotherapy [abstract] Proceedings ASCO 17 1998 73a
28. S. Vadhan-Raj, S. Patel, H.E. Broxmeyer, S.P. Reddy, and C. Bueso-Ramos et al. Phase I-II investigtion of recombinant human thrombopoietin (rhTPO) in patients with sarcoma receiving high dose chemotherapy (CT) with adriamycin (A) and ifosfamide (I) [abstract] Blood 88 1996 448a
29. S. Vadhan-Raj, L.J. Murray, C. Bueso-Ramos, S. Patel, S.P. Reddy, and W.K. Hoots et al. Stimulation of megakaryocyte and platelet production by a single dose of recombinant human thrombopoietin in patients with cancer Ann Int Med 126 1997 673 681 (Pubitemid 27184037)
30. S. Vadhan-Raj, C. Verschraegen, L. McGarry, C. Bueso-RAmos, A. Kudelka, and R. Freedman et al. Recombinant human thrombopoietin (rhTPO) attenuates high-dose carboplatin (C)-induced thrombocytopenia in patients with gynecological malignancy [abstract] Blood 90 1997 580a
31. S. Vadhan-Raj, C.F. Verschraegen, C. Bueso-Ramos, H.E. Broxmeyer, A.P. Kudelka, and R.S. Freedman et al. Recombinant human thrombopoietin attenuates carboplatin-induced severe thrombocytopenia and the need for platelet transfusions in patients with gynecologic cancer Ann Intern Med 132 2000 364 368 (Pubitemid 30127774)
32. S. Vadhan-Raj, S. Patel, C. Bueso-Ramos, J. Folloder, N. Papadopolous, and A. Burgess et al. Importance of predosing of recombinant human thrombopoietin to reduce chemotherapy-induced early thrombocytopenia J Clin Oncol 21 2003 3158 3167 (Pubitemid 46606298)
33. E. Archimbaud, O.G. Ottmann, J.A. Liu Yin, K. Lechner, H. Combret, and M.A. Sanz et al. A randomized, double-blind, placebo-controlled study with pegylated recombinant human megakaryocyte growth and development factor (PEG-rHuMGDF) as an adjunct to chemotherapy for adults with de novo acute myeloid leukemia Blood 94 1999 3694 3701
34. E. Archimbaud, O. Ottmann, J. Yin, K. Lechner, G. Heil, and M.A. Sanz et al. A randomized, double-blind, placebo-controlled study using PEG-rHuMGDF as an adjunct to chemotherapy for adults with de-novo acute myeloid leukemia (AML): early results [abstract] Blood 99 1996 447a
35. C.A. Schiffer, K. Miller, R.A. Larson, P.C. Amrein, J.H. Antin, V.J. Zani, and R.M. Stone A double-blind, placebo-controlled trial of pegylated recombinant human megakaryocyte growth and development factor as an adjunct to induction and consolidation therapy for patients with acute myeloid leukemia Blood 95 2000 2530 2535 (Pubitemid 30210530)
36. L. Cripe, D. Neuberg, and M. Tallman et al. A pilot study of recombinant human thrombopoietin (rh-TPO) and GM-CSF following induction therapy in patients older than 55 years with acute myeloid leukemia (AML) [abstract] Blood 92 1998 616a
37. J. Glaspy, J. Vredenburgh, and G.D. Demetri et al. Effects of PEGylated recombinant human megakaryocyte growth and development factor (PEG-rHuMGDF) before high dose chemotherapy (HDC) with peripheral blood progenitor cell (PBPC) support [abstract] Blood 90 1997 580a
38. D.J. Kuter, J.B. Bussel, R.M. Lyons, V. Pullarkat, T.B. Gernsheimer, and F.M. Senecal et al. Efficacy of romiplostim in patients with chronic immune thrombocytopenic purpura: A double-blind randomized controlled trial Lancet 371 2008 395 403 (Pubitemid 351181334)
39. J.B. Bussel, G. Cheng, M.N. Saleh, B. Psaila, L. Kovaleva, and B. Meddeb et al. Eltrombopag, an Oral Platelet Growth Factor, for the Treatment of Patients with Chronic Idiopathic Thrombocytopenic Purpura N Engl J Med 357 2007 2237 2247 (Pubitemid 350190754)
40. J.G. McHutchison, G. Dusheiko, M.L. Shiffman, M. Rodriguez-Torres, S. Sigal, and M. Bourliere et al. Eltrombopag for thrombocytopenia in patients with cirrhosis associated with hepatitis C N Engl J Med 357 2007 2227 2236 (Pubitemid 350190753)
41. E.S. Wang, R.M. Lyons, R.A. Larson, S. Gandhi, D. Liu, and C. Matei et al. A randomized, double-blind, placebo-controlled phase 2 study evaluating the efficacy and safety of romiplostim treatment of patients with low or intermediate-1 risk myelodysplastic syndrome receiving lenalidomide J Hematol Oncol 5 2012 71 84
42. A. Kellum, A. Jagiello-Gruszfeld, I.N. Bondarenko, R. Patwardhan, C. Messam, and Kamel Y. Mostafa A randomized, double-blind, placebo-controlled, dose ranging study to assess the efficacy and safety of eltrombopag in patients receiving carboplatin/paclitaxel for advanced solid tumors Curr Med Res Opin 26 2010 2339 2346
43. S.P. Chawla, A. Staddon, A. Hendifar, C.A. Messam, R. Patwardhan, and Y.M. Kamel Results of a phase I dose escalation study of eltrombopag in patients with advanced soft tissue sarcoma receiving doxorubicin and ifosfamide BMC Cancer 13 2012 121 130
44. S. Hayes, P.N. Mudd Jr., D. Ouellet, B.M. Johnson, D. Williams, and E. Gibiansky Population PK/PD modeling of eltrombopag in subjects with advanced solid tumors with chemotherapy-induced thrombocytopenia Cancer Chemother Pharmacol 71 2013 1507 1520
45. P. Rebulla, G. Finazzi, F. Marangoni, G. Avvisati, L. Gugliotta, and G. Tognoni et al. The threshold for prophylactic platelet transfusions in adults with acute myeloid leukemia N Engl J Med 337 1997 1870 1875
46. C.A. Schiffer, K.C. Anderson, C.L. Bennett, S. Bernstein, L.S. Elting, and M. Goldsmith et al. Platelet transfusion for patients with cancer: clinical practice guidelines of the American Society of Clinical Oncology J Clin Oncol 19 2001 1519 1538 (Pubitemid 32202560)
47. S.J. Slichter, R.M. Kaufman, S.F. Assmann, J. McCullough, D.J. Triulzi, and R.G. Strauss et al. Dose of prophylactic platelet transfusions and prevention of hemorrhage N Engl J Med 362 2010 600 613
48. S.J. Stanworth, L.J. Estcourt, G. Powter, B.C. Kahan, C. Dyer, and L. Choo et al. A no-prophylaxis platelet-transfusion strategy for hematologic cancers N Engl J Med 368 2013 1771 1780
49. G. Avvisati, J.W. ten Cate, H.R. Buller, and F. Mandelli Tranexamic acid for control of haemorrhage in acute promyelocytic leukaemia Lancet 2 1989 122 124 (Pubitemid 19180573)
50. W. Fricke, D. Alling, J. Kimble, P. Griffith, and H. Klein Lack of efficacy of tranexamic acid in thrombocytopenic bleeding Transfusion 31 4 1991 345 348
51. R.L. Gallardo, and F.H. Gardner Antifibrinolytic therapy for bleeding control during remission induction for acute leukemia Blood 62 1983 202a
52. O. Shpilberg, R. Blumenthal, O. Sofer, Y. Katz, A. Chetrit, and B. Ramot et al. A controlled trial of tranexamic acid therapy for the reduction of bleeding during treatment of acute myeloid leukemia Leukemia and Lymphoma 19 1995 141 144
53. D. Wardrop, L.J. Estcourt, S.J. Brunskill, C. Doree, M. Trivella, S. Stanworth, and M.F. Murphy Antifibrinolytics (lysine analogues) for the prevention of bleeding in patients with haematological disorders. [Review] Cochrane Database Syst Rev 7 2013 CD009733
54. A. Guarini, G.H. Sack, J. Levin, and W.R. Bell Trousseau's syndrome and other manifestations of chronic disseminated coagulopathy in patients with neoplasms: Clinical, pathologic and therapeutic features Medicine (Baltimore) 56 1977 1 37 (Pubitemid 8029158)
55. H.R. Gralnick, S. Marchesi, and H. Givelber Intravascular coagulation in acute leukemia: Clinical and subclinical abnormalities Blood 40 1972 709 718
56. M. Baccarani, G. Corbelli, G. Corbelli, L. Gugliotta, and S. Tura Defibrination in adult acute lymphoblastic leukaemia: Report of 4 cases Nouvelle Revue Francaise d'Hematologie 22 1980 115 123 (Pubitemid 10084955)
57. R.D. Gingrich, and C.P. Burns Disseminated coagulopathy in chronic myelomonocytic leukemia Cancer 44 1979 2249 2253 (Pubitemid 10210855)
58. A.K. Mangal, L. Grossman, and L. Vickars DIC in acute monoblastic leukemia: Response to heparin therapy CMAJ 130 1984 731 733
59. D. Salz-Steiner, A. Eldor, D. Vangrover, E. Okon, E. Ben-Chetrit, and E.A. Rachmilewitz et al. DIC in two patients with histiocytic medullary reticulosis Am J Clin Pathol 82 1984 119 123
60. H.R. Gralnick, and E. Abrell Studies of the procoagulant and fibrinolytic activity of promyelocytes in acute promyelocytic leukaemia Br J Haematol 24 1973 89 99
61. K. Andoh, T. Kubota, M. Takada, H. Tanaka, N. Kobayashi, and T. Maekawa Tissue factor activity in leukemia cells: Special reference to disseminated intravascular coagulation Cancer 59 1987 748 754 (Pubitemid 17018751)
62. F. Cozzolino, M. Torcia, A. Miliani, A.M. Carossino, R. Giordani, and S. Cinotti et al. Potential role of interleukin-1 as the trigger for diffuse intravascular coagulation in acute nonlymphoblastic leukemia Am J Med 84 1988 244 250
63. A. Falanga, M.G. Alessio, M.B. Donati, and T. Barbui A new procoagulant in acute leukemia Blood 71 1988 870 875
64. K.A. Bauer, and R.D. Rosenberg Thrombin generation in acute promyelocytic leukemia Blood 64 1984 791 796 (Pubitemid 14003598)
65. B. Bennett, N.A. Booth, A. Croll, and A.A. Dawson The bleeding disorder in acute promyelocytic leukaemia: Fibrinolysis due to u-PA rather than defibrination Br J Haematol 71 1989 511 517 (Pubitemid 19121334)
66. L.H. Kahle, G. Avvisati, R.J. Lamping, T. Moretti, F. Mandelli, and J.W. ten Cate Turnover of alpha-2-antiplasmin in patients with acute promyelocytic leukemia Scand J Clin Lab Invest 45 Suppl 178 1985 75 80 (Pubitemid 16223736)
67. Y. Sakata, T. Murakami, A. Noro, K. Mori, and M. Matsuda The specific activity of plasminogen activator inhibitor-1 in disseminated intravascular coagulation with acute promyelocytic leukemia Blood 77 1991 1949 1957
68. J.K. Altman, A. Rademaker, E. Cull, B.B. Weitner, Y. Ofran, and T.L. Rosenblat et al. Administration of ATRA to newly diagnosed patients with acute promyelocytic leukemia is delayed contributing to early hemorrhagic death Leuk Res 37 2013 1004 1009
69. A. Rashidi, R.K. Goudar, F. Sayedian, J.A. Vos, T.A. Goldin, N.S. Aguilera, and S.I. Fisher All-trans retinoic acid and early mortality in acute promyelocytic leukemia Leuk Res 37 2013 1391 1392
70. M.S. Tallman, B. Brenner, J. de La Serna, H. Dombret, A. Falanga, and H.C. Kwaan et al. Meeting report: Acute promyelocytic leukemia coagulopathy workshop, January/2004, London, United Kingdom Leuk Res 9 2005 347 351
71. J. Milutinovic, S. Irby, and M. Fisher Hemolytic uremic syndrome and metastatic malignancy South Med J. 75 1982 1409 1411
72. S.J. Rabadi, J.D. Khandekar, and H.J. Miller Mitomycin-induced hemolytic uremic syndrome: case presentation and review of literature Cancer Treat Rep 66 5 1982 1244 1247 (Pubitemid 12090398)
73. M.E. Weinblatt, E. Kahn, P.G. Scimeca, and J.A. Kochen Hemolytic uremic syndrome associated with cisplatin therapy Am J Pediatr Hematol Oncol 9 4 1987 295 298 (Pubitemid 18009268)
74. K. Lhotta, T. Kuhr, H.J. Rumpelt, E. Woll, J. Thaler, and P. Konig Thrombotic microangiopathy with renal failure in two patients undergoing gemcitabine chemotherapy Am J Nephrol 19 1999 590 593
75. M.C. Fung, A.M. Storniolo, B. Nguyen, M. Arning, W. Brookfield, and J. Vigil A review of hemolytic uremic syndrome in patients treated with gemcitabine therapy Cancer 85 1999 2023 2032 (Pubitemid 29202779)
76. J. Niu, and M.P. Mims Oxaliplatin-induced thrombotic thrombocytopenic purpura: case report and literature review. [Review] J Clin Oncol 30 2012 e312 e314
77. A.A. Kaplan Therapeutic apheresis for cancer related hemolytic uremic syndrome [Review] Ther Apher 4 2000 201 206 (Pubitemid 30445872)
78. S.K. Vesely, J.N. George, B. Lammle, J.D. Studt, L. Alberio, and M.A. El-Harake et al. ADAMTS13 activity in thrombotic thrombocytopenic purpura-hemolytic uremic syndrome: relation to presenting features and clinical outcomes in a prospective cohort of 142 patients Blood 102 2003 60 68 (Pubitemid 36759636)
79. M. Levandovsky, D. Harvey, P. Lara, and T. Wun Thrombotic thrombocytopenic purpura-hemolytic uremic syndrome (TTP-HUS): A 24-year clinical experience with 178 patients J Hematol Oncol 1 2008 23 31
80. A.I. Kuznetsov, A.L. Ivanov, L.I. Idelson, and A.V. Mazurov Mechanisms of thrombocytopenia in patients with lymphoproliferative diseases Eur J Haematol 49 1992 113 118
81. R.W. Carey, A. McGinnis, B.M. Jacobson, and A. Carvalho Idiopathic thrombocytopenic purpura complicating chronic lymphocytic leukemia Arch Intern Med 136 1976 62 66
82. B.R. Kaden, W.F. Rosse, and T.W. Hauch Immune thrombocytopenia in lymphoproliferative diseases Blood 53 1979 545 551 (Pubitemid 9148992)
83. U. Duhrsen, W. Augener, T. Zwingers, and G. Brittinger Spectrum and frequency of autoimmune derangements in lymphoproliferative disorders: Analysis of 637 cases and comparison with myeloproliferative diseases Br J Haematol 67 1987 235 239 (Pubitemid 18029659)
84. S.H. Lim, and J.J. Ifthikharuddin Autoimmune thrombocytopenic purpura complicating lymphoproliferative disorders Leuk Lymphoma. 15 1994 61 64 (Pubitemid 24303380)
85. A.W. Berkman, T. Kickler, and H. Braine Platelet-associated IgG in patients with lymphoma Blood 63 1984 944 948 (Pubitemid 14141320)
86. D.B. Rubinstein, and D.L. Longo Peripheral destruction of platelets in chronic lymphocytic leukemia: recognition, prognosis and therapeutic implications Am J Med 71 1981 729 732 (Pubitemid 12140441)
87. T.J. Hamblin, D.G. Oscier, and B.J. Young Autoimmunity in chronic lymphocytic leukaemia J Clin Pathol 39 1986 713 716 (Pubitemid 16069477)
88. N. Xiros, T. Binder, B. Anger, J. Bohlke, and H. Heimpel Idiopathic thrombocytopenic purpura and autoimmune hemolytic anemia in Hodgkin's disease Eur J Haematol 40 1988 437 441
89. M.V. Dhodapkar, C.Y. Li, J.A. Lust, A. Tefferi, and R.L. Phyliky Clinical spectrum of clonal proliferations of T-large granular lymphocytes: A T-cell clonopathy of undetermined significance? Blood 84 1994 1620 1627 (Pubitemid 24273033)
90. U. Duhrsen, W. Augener, T. Zwingers, and G. Brittinger Spectrum and frequency of autoimmune derangements in lymphoproliferative disorders: Analysis of 637 cases and comparison with myeloproliferative diseases Br J Haematol 67 1987 235 239 (Pubitemid 18029659)
91. W. Barcellini, S. Capalbo, R.M. Agostinelli, F.R. Mauro, A. Ambrosetti, and R. Calori et al. Relationship between autoimmune phenomena and disease stage and therapy in B-cell chronic lymphocytic leukemia Haematologica 91 2006 1689 1692 (Pubitemid 46032967)
92. C. Visco, M. Ruggeri, E.M. Laura, R. Stasi, R. Zanotti, and I. Giaretta et al. Impact of immune thrombocytopenia on the clinical course of chronic lymphocytic leukemia Blood 111 2008 1110 1116 (Pubitemid 351213389)
93. S. Mittal, M.G. Blaylock, D.J. Culligan, R.N. Barker, and M.A. Vickers A high rate of CLL phenotype lymphocytes in autoimmune hemolytic anemia and immune thrombocytopenic purpura Haematologica 93 2008 151 152 (Pubitemid 351156170)
94. U.M. Hedge, A. Zuiable, S. Ball, and B.L. Roter The relative incidence of idiopathic and secondary autoimmune thrombocytopenia: A clinical and serological evaluation in 508 patients Clin Lab Haematol 7 1985 7 16 (Pubitemid 15086854)
95. U.P. Hegde, W.H. Wilson, T. White, and B.D. Cheson Rituximab treatment of refractory fludarabine-associated immune thrombocytopenia in chronic lymphocytic leukemia Blood 100 2002 2260 2262 (Pubitemid 35001267)
96. F. Zaja, N. Vianelli, A. Sperotto, F. Patriarca, M. Tani, and L. Marin et al. Anti- CD20 therapy for chronic lymphocytic leukemia-associated autoimmune diseases Leuk Lymphoma 44 2003 1951 1955 (Pubitemid 37369630)
97. N. Gupta, S. Kavuru, D. Patel, D. Janson, N. Driscoll, S. Ahmed, and K.R. Rai Rituximab-based chemotherapy for steroid refractory autoimmune hemolytic anemia of chronic lymphocytic leukemia Leukemia 16 2002 2092 2095 (Pubitemid 35203453)
98. G.A. Pangalis, M.N. Dimopoulou, M.K. Angelopoulou, C. Tsekouras, T.P. Vassilakopoulos, and G. Vaiopoulos et al. Campath-1H (anti-CD52) monoclonal antibody therapy in lymphoproliferative disorders Med Oncol 18 2001 99 107 (Pubitemid 32929482)
99. E. Ammatuna, C. Marino, M.E. Mitra, G. Calvaruso, and E. Iannitto Successful treatment of steroid resistant autoimmune thrombocytopenia associated with chronic lymphocytic leukemia with alemtuzumab Eur J Haematol 73 2004 225226
100. A. Cuker, A.J. Coles, H. Sullivan, E. Fox, M. Goldberg, and P. Oyuela et al. A distinctive form of immune thrombocytopenia in a phase 2 study of alemtuzumab for the treatment of relapsing-remitting multiple sclerosis Blood 118 2011 6299 05
101. G. D'Arena, and N. Cascavilla Romiplostim for chronic lymphocytic leukemia-associated immune thrombocytopenia Leuk Lymphoma 52 2011 701 704
102. M. Sinisalo, M. Sankelo, and M. Itala-Remes Thrombopoietin receptor agonists can be used temporarily with patients suffering from refractory chronic lymphocytic leukemia-associated immunologic thrombocytopenia Leuk Lymphoma 52 2011 724 725
103. S. Gudbrandsdottir, H. Frederiksen, and H. Hasselbalch Thrombopoietin-receptor agonists in haematological disorders: the Danish experience Platelets 23 2012 423 429
104. S. Koehrer, M.J. Keating, and W.G. Wierda Eltrombopag, a second-generation thrombopoietin receptor agonist, for chronic lymphocytic leukemia-associated ITP Leukemia 24 2010 1096 1098
105. R.A. Rudders, A.C. Aisenberg, and A.L. Schiller Hodgkin's disease presenting as "idiopathic" thrombocytopenic purpura Cancer 30 1972 220 230
106. S.J. Bradley, G.V. Hudson, and D.C. Linch Idiopathic thrombocytopenic purpura in Hodgkin's disease: A report of eight cases Clin Oncol (R Coll Radiol) 5 1993 355 357 (Pubitemid 24005057)
107. G. Martinelli, P.L. Zinzani, M. Magagnoli, N. Vianelli, and S. Tura Incidence and prognostic significance of idiopathic thrombocytopenic purpura in patients with Hodgkin's disease in complete hematological remission Haematologica 83 1998 669 670 (Pubitemid 28364085)
108. O. Landgren, E.A. Engels, R.M. Pfeiffer, G. Gridley, L. Mellemkjaer, and J.H. Olsen et al. Autoimmunity and susceptibility to Hodgkin lymphoma: A population-based case-control study in Scandinavia J Natl Cancer Inst 98 2006 1321 1330 (Pubitemid 44530727)
109. J.J. Kirshner, K.W. Zamkoff, and A.J. Gottlieb Idiopathic thrombocytopenic purpura and Hodgkin's disease: report of two cases and a review of the literature Am J Med Sci 280 1980 21 28 (Pubitemid 10002469)
110. J.R. Cohen Idiopathic thrombocytopenic purpura in Hodgkin's disease: A rare occurrence of no prognostic significance Cancer 41 1978 743 746 (Pubitemid 8292586)
111. S.E. Jones Autoimmune disorders and malignant lymphoma Cancer 31 1973 1092 1098
112. M.W. Wlodarski, C. O'Keefe, E.C. Howe, A.M. Risitano, A. Rodriguez, and I. Warshawsky et al. Pathologic clonal cytotoxic T-cell responses: nonrandom nature of the T-cell receptor restriction in large granular lymphocyte leukemia Blood 106 2005 2769 2780 (Pubitemid 41510753)
113. P.A. Kouides, and J.M. Rowe Large granular lymphocyte leukemia presenting with both amegakaryocytic thrombocytopenic purpura and pure red cell aplasia: clinical course and response to immunosuppressive therapy Am J Hematol 49 1995 232 236
114. D. Ergas, A. Tsimanis, M. Shtalrid, C. Duskin, and A. Berrebi T-gamma large granular lymphocyte leukemia associated with amegakaryocytic thrombocytopenic purpura, Sjogren's syndrome, and polyglandular autoimmune syndrome type II, with subsequent development of pure red cell aplasia Am J Hematol 69 2002 132 134 (Pubitemid 34111166)
115. D.W. Lai, T.P. Loughran Jr, J.P. Maciejewski, S. Sasu, S.X. Song, and P.K. Epling-Burnette et al. Acquired amegakaryocytic thrombocytopenia and pure red cell aplasia associated with an occult large granular lymphocyte leukemia Leuk Res 32 2008 823 827 (Pubitemid 351323925)
116. J. Ru, and H.A. Liebman Successful treatment of refractory pure red cell aplasia associated with lymphoproliferative disorders with the anti-CD52 monoclonal antibody Alemtuzumab (CAMPATH-1H) Br J Haematol 123 2003 278 281 (Pubitemid 37305062)